Evidence map›Paper›PMID 26716896›Full record

Trial reportOncotarget2016

Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.

Nan Ji, Danhui Weng, Cang Liu, Zheng Gu, Shizhang Chen, Ying Guo, Zhong Fan, Xiao Wang, Jianfei Chen, Yanyan Zhao and 4 more

Registry-linked trialOpen access · diamondAbstract readClinical Trial, Phase IIComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00870181 (Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma), which is not on this map. Cited by 55 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 7 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00870181 phase2completednot on this map

Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma

TypeinterventionalSponsorHuazhong University of Science and TechnologyRan2008 to 2012Enrolled47ConditionsMalignant Glioma of Brain, GlioblastomaArmsADV-TK/GCV, Surgery, systemic chemotherapy
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 7 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Cell and gene therapy in neuro-oncology.Handbook of clinical neurology · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Nan JiDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R. China.
Danhui WengTongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, P.R. China.
Cang LiuBeijing Friendship Hospital, Capital Medical University, Beijing, P.R. China.
Zheng GuBeijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China.
Shizhang ChenBeijing YouAn Hospital, Capital Medical University, Beijing, P.R. China.
Ying GuoBeijing YouAn Hospital, Capital Medical University, Beijing, P.R. China.
Zhong FanBeijing YouAn Hospital, Capital Medical University, Beijing, P.R. China.
Xiao WangBeijing YouAn Hospital, Capital Medical University, Beijing, P.R. China.
Jianfei ChenBeijing YouAn Hospital, Capital Medical University, Beijing, P.R. China.
Yanyan ZhaoBeijing YouAn Hospital, Capital Medical University, Beijing, P.R. China.
Jianfeng ZhouTongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, P.R. China.
Jisheng WangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R. China.
Ding MaTongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, P.R. China.
Ning LiBeijing YouAn Hospital, Capital Medical University, Beijing, P.R. China.
Capital Medical University · CNBeijing YouAn Hospital · CNHuazhong University of Science and Technology · CNBeijing Friendship Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis randomized, open-label, multicenter, phase II clinical trial was conducted to assess the anti-tumor efficacy and safety of replication-deficient adenovirus mutant thymidine kinase (ADV-TK) in combination with ganciclovir administration in patients with recurrent high-grade glioma (HGG). PATIENTS AND

methods53 patients with recurrent HGG were randomly allocated to receive intra-arterial cerebral infusion of ADV-TK or conventional treatments. The primary end point was 6-month progression-free survival (PFS-6). Secondary end points included progression-free survival (PFS), overall survival (OS), safety, and clinical benefit. This trial is registered with Clinicaltrials.gov, NCT00870181.

resultsIn ADV-TK group, PFS-6 was 54.5%, the median PFS was 29.6 weeks, the median OS was 45.4 weeks, and better survivals were achieved when compared with control group. The one-year PFS and OS were 22.7% and 44.6% in ADV-TK group respectively, and clinical benefit was 68.2%. There are 2 patients alive for more than 4 years without progression in ADV-TK group. In the subgroup of glioblastoma received ADV-TK, PFS-6 was 71.4%, median PFS was 34.9 weeks, median OS was 45.7 weeks respectively, much better than those in control group. The one-year PFS and OS were 35.7% and 50.0% in ADV-TK group respectively. ADV-TK/ganciclovir gene therapy was well tolerated, and no treatment-related severe adverse events were noted.

conclusionOur study demonstrated a notable improvement of PFS-6, PFS and OS in ADV-TK treated group, and the efficacy and safety appear to be comparable to other reported treatments used for recurrent HGG. ADV-TK gene therapy is therefore a valuable therapeutic option for recurrent HGG.

Indexed as

Genetic TherapyAdenoviridaeAdultAgedAntiviral AgentsBrain NeoplasmsCase-Control StudiesCombined Modality TherapyFemaleFollow-Up StudiesGanciclovirGenetic VectorsGliomaHumansMaleMiddle AgedAntiviral AgentsGanciclovirThymidine KinaseADV-TKgene therapyglioblastomarecurrent high-grade glioma

Identifiers

PMID26716896
PMCPMC4826211
OpenAlexW2209618509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.